Actually there could be a slight difference in the patient population for the two drugs. The abiraterone population included patients treated twice with chemo which means there probably were patients already treated with docetaxel and then mitoxantrone. In the cabazitaxel study patients who had previously received mitoxantrone were excluded so i imagine the patient population was strictly 1st line and less sick than the patients in the abiraterone study.
I believe Abiraterone's bigger opportunity is as an option for chemo/biologic naive patients who fail anti-androgens in other words as a second-line hormone therapy (#msg-55413563).
News 
Market Data 
Discover 
